Altimmune, Inc. (ALT) - What Are Researchers Saying About This Stock?

Key Points

• Analyst sentiment is moderately positive: Altimmune has a consensus “Moderate Buy” rating from 10 analysts, with eight buys, one hold and one sell. The average 12-month price target is $14.33.
• The stock remains highly speculative: Shares opened at $2.23, near the one-year low of $2.17, while the company reported a quarterly loss of $0.12 per share and analysts expect a full-year loss of $0.58 per share.
• Institutional ownership is substantial: Hedge funds and other institutional investors own 78.05% of Altimmune, whose lead candidate, pemvidutide, is being developed for obesity, metabolic diseases and MASH.

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has received a consensus rating of "Moderate Buy" from the ten research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $14.33.

Several brokerages recently weighed in on ALT. Leerink Partners initiated coverage on Altimmune in a research report on Monday, June 22nd. They issued an "outperform" rating and a $10.00 price objective for the company. Weiss Ratings restated a "sell (d-)" rating on shares of Altimmune in a research report on Monday, September 21st. HC Wainwright reaffirmed a "buy" rating on shares of Altimmune in a research note on Tuesday, July 28th. Wall Street Zen raised Altimmune from a "strong sell" rating to a "sell" rating in a research note on Saturday, June 27th. Finally, Evercore reiterated an "outperform" rating on shares of Altimmune in a report on Wednesday, September 23rd.

Altimmune Stock Performance

Altimmune stock opened at $2.23 on Tuesday. The firm has a 50 day simple moving average of $2.99 and a 200-day simple moving average of $2.99. The stock has a market cap of $433.78 million, a price-to-earnings ratio of -2.86 and a beta of 0.06. The company has a debt-to-equity ratio of 0.07, a current ratio of 26.78 and a quick ratio of 26.78. Altimmune has a 1-year low of $2.17 and a 1-year high of $6.44.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02. On average, analysts expect that Altimmune will post -0.58 EPS for the current year.

Institutional Trading of Altimmune

Several institutional investors and hedge funds have recently bought and sold shares of ALT. Cetera Investment Advisers increased its holdings in shares of Altimmune by 19.4% in the 1st quarter. Cetera Investment Advisers now owns 35,453 shares of the company's stock valued at $109,000 after acquiring an additional 5,766 shares during the last quarter. Vontobel Holding Ltd. lifted its stake in Altimmune by 23.1% during the third quarter. Vontobel Holding Ltd. now owns 30,787 shares of the company's stock worth $88,000 after purchasing an additional 5,787 shares during the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Altimmune by 26.0% in the first quarter. The Manufacturers Life Insurance Company now owns 34,763 shares of the company's stock valued at $107,000 after purchasing an additional 7,167 shares in the last quarter. North Star Investment Management Corp. boosted its holdings in Altimmune by 112.5% in the first quarter. North Star Investment Management Corp. now owns 17,000 shares of the company's stock valued at $52,000 after purchasing an additional 9,000 shares in the last quarter. Finally, AXQ Capital LP boosted its holdings in Altimmune by 19.0% in the second quarter. AXQ Capital LP now owns 56,810 shares of the company's stock valued at $173,000 after purchasing an additional 9,058 shares in the last quarter. 78.05% of the stock is currently owned by hedge funds and other institutional investors.

About Altimmune

Altimmune, Inc NASDAQ: ALT is a clinical-stage biotechnology company developing peptide-based therapeutics for metabolic and liver diseases. The company's lead product candidate is pemvidutide, an investigational dual GLP-1 and glucagon receptor agonist being studied for chronic weight management and metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH).

Altimmune's development programs are focused on addressing obesity, related metabolic conditions and chronic liver disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.